$ISRG

Intuitive surgical systems were used in an average of over 10,000 procedures a day.

Intuitive Surgical (ISRG) reported Q3 2026 revenue of $3.05B, up 22% YoY. Procedures grew 15% YoY, with da Vinci systems up 14% and Ion up 31%. GAAP net income was $523M, or $1.49 per share, including a $450M litigation charge. Non-GAAP net income was $1.05B, or $3.00 per share. The company placed 546 da Vinci and 56 Ion systems. ISRG expects 14-15% procedure growth for 2026 and non-GAAP gross margin of 68.7-69.3%.

Original reporting
Published Oct 20, 2026, 8:05 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 8:08 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ISRG
Neutral
high confidence
Mentioned
$ISRG
Relevance
8/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ISRGNeutralHigh
01

Why it matters

The mixed earnings outcome may lead to modest price volatility as investors digest both strong top‑line growth and lower profitability.

02

Market read

The release provides fresh earnings data and guidance that can affect ISRG and peers in the medical device space.

03

What to watch

Tariff impact on margins and the pace of system placements may limit future profitability.

Relevance 8/10Novelty 9/10Timing: today

Background

Intuitive Surgical reported its Q3 2026 financial results, highlighting system placements, procedure growth, and a large share repurchase.

Company-level read

Ticker impact

$ISRGNeutralHigh confidence
Context

Q3 2026 earnings release with revenue up 22% to $3.05B and GAAP net income down 26% to $523M, plus a $2.94B share repurchase and $450M litigation settlement.

Expected impact

likely pressure as investors weigh lower earnings against strong revenue growth and sizable buyback.

Evidence & confidence

The earnings beat on revenue but miss on profit, combined with a $2.94B repurchase, creates mixed signals that may temper price gains.

Market effects

reinforces growth narrative for surgical robotics and minimally invasive device sector.

supports US healthcare equipment market sentiment with higher procedure volumes.

signals continued global demand for robotic surgery platforms.

Counterpoint

The settlement charge and declining GAAP profit could outweigh revenue growth, prompting a short‑term pullback.

Key entities

  • Intuitive Surgical

    US‑listed maker of da Vinci and Ion surgical systems.

Related articles

$ISRGMedAI 8/10

Intuitive Surgical, Inc (ISRG) Q3 2026 Earnings Call Transcript

Intuitive Surgical (ISRG) reported Q3 2026 earnings, highlighting 15% total procedure growth, with 14% in da Vinci and 31% in Ion procedures. U.S. da Vinci growth was 10%, while international growth was 20%. The company installed over 13,200 da Vinci and Ion systems worldwide. Revenue growth was driven by strong demand for da Vinci 5 and SP platforms, with 28% increase in system placements. The company also announced plans for a new manufacturing facility in Malaysia.

$ISRGMedAI 8/10

Intuitive Surgical (ISRG) Q3 Earnings Beat Expectations with Str

Intuitive Surgical (ISRG) reported Q3 earnings that surpassed expectations, with revenue of $3.05B, up 21.5% YoY, and EPS of $3.00. The company saw a 15% rise in procedures and placed 546 new da Vinci systems. ISRG's GF Value suggests it is undervalued by 31.1%, with a GF Score of 96/100. Insiders sold $93.4M in shares, while gurus show mixed activity.